Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NYSEMKT:PVCT
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $0.05
- 200 Day Moving Avg: $0.03
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
Frequently Asked Questions for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
What is Provectus Biopharmaceuticals' stock symbol?
Provectus Biopharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PVCT."
Who are some of Provectus Biopharmaceuticals' key competitors?
Some companies that are related to Provectus Biopharmaceuticals include Oramed Pharmaceuticals (ORMP), Quotient Ltd (QTNT), Fulgent Genetics (FLGT), Vermillion (VRML), Endocyte (ECYT), Proteostasis Therapeutics (PTI), Zafgen (ZFGN), Rexahn Pharmaceuticals (RNN), Cogentix Medical (CGNT), Affimed NV (AFMD), Agile Therapeutics (AGRX), T2 Biosystems (TTOO), Pfenex (PFNX), Applied Genetic Technologies Corp (AGTC), Vericel Corp (VCEL), Alimera Sciences (ALIM), Axsome Therapeutics (AXSM) and Five Star Senior Living (FVE).
How do I buy Provectus Biopharmaceuticals stock?
Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Provectus Biopharmaceuticals stock cost?
One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.83.
Consensus Ratings for Provectus Biopharmaceuticals (NYSEMKT:PVCT) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)Earnings History by Quarter for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
Latest Headlines for Provectus Biopharmaceuticals (NYSEMKT:PVCT)
|Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board|
finance.yahoo.com - April 20 at 7:29 PM
|Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group|
finance.yahoo.com - April 7 at 12:08 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 31 at 7:34 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disc|
biz.yahoo.com - March 23 at 7:53 PM
|Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment|
finance.yahoo.com - March 23 at 7:53 PM
|Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus|
us.rd.yahoo.com - March 6 at 8:43 AM
|Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline|
us.rd.yahoo.com - February 24 at 8:36 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - February 15 at 12:01 AM
|Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering - PR Newswire (press release)|
www.prnewswire.com - February 12 at 8:28 AM
|Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering|
finance.yahoo.com - February 10 at 9:47 PM
|PROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modificat|
biz.yahoo.com - February 8 at 9:37 PM
|How These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma|
www.bizjournals.com - February 3 at 8:20 PM
|Provectus commences rights offering to stockholders - Seeking Alpha|
seekingalpha.com - February 1 at 10:11 PM
|Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants|
finance.yahoo.com - January 31 at 9:19 PM
|Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO - Business Wire (press release)|
www.businesswire.com - December 31 at 12:46 AM